IBD Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.
Gastroenterology Unit, A.R.N.A.S. Civico, Palermo, Italy.
Dig Liver Dis. 2018 Dec;50(12):1292-1298. doi: 10.1016/j.dld.2018.06.008. Epub 2018 Jun 22.
Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis.
We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis.
118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up.
Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in golimumab patients (p = 0.008) at the end of follow up. These data were confirmed by propensity score analysis. A further analysis considering adalimumab optimization as treatment failure showed that the difference between adalimumab and golimumab was not significant.
Adalimumab and golimumab are effective in the treatment of ulcerative colitis. Adalimumab seems to be more effective than golimumab. This difference is probably affected by the impossibility of golimumab to be optimized in Italy while adalimumab is.
阿达木单抗和古利姆单抗在治疗中重度溃疡性结肠炎方面均有效。
我们报告了阿达木单抗和古利姆单抗治疗溃疡性结肠炎的疗效比较。
纳入 118 例接受阿达木单抗治疗和 79 例接受古利姆单抗治疗的患者，并在第 8 周和随访结束时进行评估。
第 8 周时总体临床获益率为 72.6%，随访结束时为 58.9%。疾病持续时间较长和接受阿达木单抗治疗的患者具有更好的疗效。第 8 周时，阿达木单抗组的临床获益率为 78.8%，古利姆单抗组为 63.3%（p=0.026）；随访结束时，阿达木单抗组为 66.9%，古利姆单抗组为 46.8%（p=0.008）。这些数据通过倾向评分分析得到了证实。进一步考虑将阿达木单抗优化作为治疗失败的分析表明，阿达木单抗和古利姆单抗之间的差异无统计学意义。
阿达木单抗和古利姆单抗在溃疡性结肠炎的治疗中均有效。阿达木单抗似乎比古利姆单抗更有效。这种差异可能是由于在意大利无法对古利姆单抗进行优化，而阿达木单抗则可以。
